Article
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Thrombosis research - 1 Apr 2012
Kassimis George, Davlouros Periklis, Xanthopoulou Ioanna, Stavrou Eleana F, Athanassiadou Aglaia, Alexopoulos Dimitrios
Abstract excerpt
INTRODUCTION: Information regarding any possible additional effect of genetic variants other than CYP2C19*2 on platelet reactivity in patients undergoing percutaneous coronary intervention (PCI), while on dual antiplatelet therapy, is sparse. MATERIALS AND METHODS: Genotyping for CYP2C19*2, CYP2C19*17, CYP2C9*3, CYP2B6*5, ABCB1 and P2RY12 (c.-217+2739T>C) variants was performed in 146 consecutive PCI patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
